



## May Insights

### HESI at SETAC Europe



**SETAC EUROPE 28<sup>th</sup> ANNUAL MEETING**  
13–17 MAY 2018 | ROME, ITALY  
Responsible and Innovative Research for Environmental Quality



HESI will be well represented at the upcoming **28th Society of Environmental Toxicology and Chemistry (SETAC) Europe Annual Meeting** in Rome, Italy, on **13–17 May 2018**. The following is a list of presentations involving HESI committee work or HESI staff.

#### Monday, 14 May 2018

- **Platform presentation 170:** Ecological threshold for toxicological concern (ecoTTC): applications for environmental risk assessment in various contexts. *Presentation by Michelle Embry (HESI) on behalf of the Animal Alternatives in ERA Technical Committee.*
- **Poster MO165:** Optimization and accessibility of the ecoTTC database and tool. *Presentation by Ryan Otter (MTSU) on behalf of the Animal Alternatives in ERA Technical Committee.*
- **Poster MO169:** Assessing the bioaccumulation potential of several pharmaceuticals using fish S9 and hepatocyte assays. *Presentation by Lisa Constantine (Pfizer); Michelle Embry (HESI) co-author.*

#### Thursday, 17 May 2018

- **Platform presentation 552:** Application of new statistical distribution approaches for mixture risk assessment. *Presentation by Aude Kienzler (EC JRC) as part of the Animal Alternatives in ERA Technical Committee work.*
- **Platform presentation 598:** Setting the stage to advance the adverse outcome pathway framework through horizon scanning. *Presentation by Carlie LaLone (USEPA); Michelle Embry (HESI) co-author.*
- **Platform presentation 601:** Use of adverse outcome pathways to inform decisions on chemical innovation, regulation & stewardship. *Presentation by Thomas Hill (USEPA); Michelle Embry (HESI) co-author.*
- **Platform presentation 665:** Critical evaluation of a human *in vitro* biotransformation rate database: case study of seven chemicals. *Presentation by Karen Foster (KFER); Michelle Embry (HESI) co-author.*
- **Poster TH041:** A tiered testing strategy for rapid estimation of bioaccumulation by a combined modeling – *in vitro* testing approach: derivation of kinetic rate constants in different *in vitro* models. *Presentation by Kristin Schirmer (Eawag); Michelle Embry (HESI) co-author.*
- **Poster TH042:** Update on development of OECD Test Guidelines and Guidance Document on determination of fish *in vitro* hepatic clearance. *Presentation by Michelle Embry (HESI) on behalf of the Bioaccumulation Technical Committee.*
- **Poster TH043:** The Bioaccumulation Assessment Tool (BAT): a quantitative weight of evidence approach for bioaccumulation assessment. *Presentation by Liisa Toose (ARC); Michelle Embry (HESI) co-author.*
- **Poster TH049:** Towards developing a list of reference chemicals for endocrine assay validation. *Presentation by Chris Prosser (ExxonMobil) and Michelle Embry (HESI).*
- **Poster TH287:** Developing a strategy to improve the environmental risk assessment of difficult to test multi-component substances: a new HESI Emerging Issues Committee. *Presentation*

---

## LAST CALL: Register for the Cardiac Safety Committee Meeting



The Cardiac Safety Committee will host a face-to-face meeting on **15–16 May 2018** at the Langham Hotel in Boston, Massachusetts.

Registration is required for this event and will be free to all committee members. The fee-waived code for members is hesi123. Please complete your registration online [here](#) as soon as possible. Additional meeting details will be posted on the event page when available.

---

## New Advances in Drug-Induced Arrhythmias, Focusing on the Comprehensive *In Vitro* Proarrhythmia Assay (CiPA)

This event will be held **21–22 May 2018** in Washington, DC. CiPA hopes to make drug development more efficient by replacing the current QT and hERG-based approach with a new drug testing paradigm focused on preclinical data to determine if a drug is proarrhythmic instead of prolonging the QTc interval. Scientific data supporting CiPA will be presented as well as the next ICH steps.

Register online [here](#) and visit the CSRC website for the full meeting details [here](#).

---

## Upcoming CT-TRACS Meeting

The forthcoming **IABS/CIRM Symposium “4th Cell Therapy Conference” (5–6 June 2018;** registration open) and a **joint CT-TRACS workshop (7 June 2018;** by invitation) will be held in Los Angeles, California. CT-TRACS members will participate in “session III, day 2” of the main conference to talk about predictive methods to assess the tumorigenicity of human cell-based therapeutic products, and they will hold focused discussions with key stakeholders to address the need for consensus regarding best approaches for the tumorigenicity evaluation of pluripotent stem cell-based products. Further details are available [here](#).

---

## 2018 HESI Annual Meeting



The **2018 HESI Annual Meeting** will be held **12–13 June 2018** in Washington, DC. This year’s meeting will feature exciting new science on risk assessment and big data, and we will hear from the HESI THRIVE awardees. The draft agenda is now available on the website [here](#). Check the [meeting website](#) to learn more!

---

## Registration Now Open: Gut Microbiome Workshop

The HESI Microbiome Subcommittee is proud to announce “**The Gut Microbiome: Markers of Human Health, Drug Efficacy and Xenobiotic Toxicity Workshop**,” which will be held in Alexandria, Virginia, on **25–26 June 2018**. The workshop will focus on:

- current science on the gut microbiome and identification of areas of interest regarding its role in human health
- our understanding of how xenobiotic toxicity affects the microbiome
- discussion of biomarkers of disease or organ damage due to alterations of microbiome structure or endogenous microbial metabolites



---


### Recent Publications

Millard D, Dang Q, Shi H, Zhang X, Strock C, Kraushaar U, Zeng H, Levesque P, Lu HR, Guillon JM, Wu JC, Li Y, Luerman G, Anson B, Guo L, Clements M, Abassi YA, Ross J, Pierson J, Gintant G (2018) Cross-site reliability of human induced pluripotent stem-cell derived cardiomyocyte based safety assays using microelectrode arrays: results from a blinded CiPA pilot study. *Toxicological Sciences*. Published online ahead of print. <https://doi.org/10.1093/toxsci/kfy110>.

---

### From the Executive Director

At HESI's Annual Meeting, we have an exciting opportunity to celebrate the breadth of quality science underway at HESI and to build a shared vision for the coming year. This year's meeting will challenge all of us to think in new ways about opportunities to further broaden HESI's positive impact on health and the environment. Registration is free, but space is limited and filling fast. I look forward to seeing you there!



Sybil Pettit  
HESI Executive Director

ILSI Health and Environmental Sciences Institute (HESI)

740 Fifteenth Street, NW  
6th Floor

Washington, DC 20005-1743

| 202.659.3306 | 202.659.3859 | [HESI@hesiglobal.org](mailto:HESI@hesiglobal.org) | [www.hesiglobal.org](http://www.hesiglobal.org)

STAY CONNECTED

